GlassScriptPhysician profile
Michael Joseph Macikowski
NPI 1174878086
$2,533.88
in general payments reported to CMS, 2019-2025
22 companies · $883 in 2025
The $883 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $154 · 2023: $681 · 2024: $816 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,380.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $929.45 | 2022-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amgen INC. | $350.90 | 2023-2024 | Repatha |
| Pfizer INC. | $183.16 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $179.72 | 2022-2025 | Farxiga, Wainua |
| Abbott Laboratories | $126.26 | 2024 | Mitraclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.31 | 2023-2025 | Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $88.81 | 2022-2023 | Arcalyst |
| Janssen Pharmaceuticals, INC | $85.00 | 2022-2024 | Xarelto |
| Bridgebio Pharma, INC. | $72.02 | 2025 | Attruby |
| Cvrx, INC. | $64.28 | 2025 | Barostim Neo System |
| Scpharmaceuticals INC. | $40.82 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $37.39 | 2022-2023 | Camzyos |
| Novartis Pharmaceuticals Corporation | $34.96 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.88 | 2022-2024 | Lifevest |
| Kestra Medical Technology Services, INC. | $31.26 | 2025 | Assure Wcd |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $30.35 | 2024 | Watchman Flx |
| Lexicon Pharmaceuticals, INC. | $30.18 | 2024 | |
| W. L. Gore & Associates, INC. | $30.12 | 2023 | Gore Cardioform Septal Occluder |
| Abiomed | $23.96 | 2025 | |
| Alnylam Pharmaceuticals INC. | $21.37 | 2023 | Onpattro |
| Merck Sharp & Dohme LLC | $16.65 | 2025 | Winrevair |
| Esperion Therapeutics, INC. | $14.03 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Macikowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.